MX372775B - Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas. - Google Patents

Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.

Info

Publication number
MX372775B
MX372775B MX2015013173A MX2015013173A MX372775B MX 372775 B MX372775 B MX 372775B MX 2015013173 A MX2015013173 A MX 2015013173A MX 2015013173 A MX2015013173 A MX 2015013173A MX 372775 B MX372775 B MX 372775B
Authority
MX
Mexico
Prior art keywords
methods
cell
cftr
chronic obstructive
obstructive pulmonary
Prior art date
Application number
MX2015013173A
Other languages
English (en)
Spanish (es)
Other versions
MX2015013173A (es
Inventor
Erik Schwiebert
Hongwu Gao
John Dixon
John Streiff
Original Assignee
Discoverybiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discoverybiomed Inc filed Critical Discoverybiomed Inc
Publication of MX2015013173A publication Critical patent/MX2015013173A/es
Publication of MX372775B publication Critical patent/MX372775B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2015013173A 2013-03-15 2014-03-14 Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas. MX372775B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788353P 2013-03-15 2013-03-15
PCT/US2014/027079 WO2014152213A2 (en) 2013-03-15 2014-03-14 Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders

Publications (2)

Publication Number Publication Date
MX2015013173A MX2015013173A (es) 2016-04-04
MX372775B true MX372775B (es) 2020-06-29

Family

ID=51581684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013173A MX372775B (es) 2013-03-15 2014-03-14 Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.

Country Status (9)

Country Link
US (1) US9815825B2 (https=)
EP (1) EP2970248B1 (https=)
JP (1) JP6514680B2 (https=)
KR (1) KR20150131309A (https=)
CN (1) CN105121437B (https=)
AU (1) AU2014240026B2 (https=)
CA (1) CA2903103C (https=)
MX (1) MX372775B (https=)
WO (1) WO2014152213A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158913A2 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
EP2922852A4 (en) 2012-11-20 2016-05-25 Discoverybiomed Inc SMALL MOLECULAR CFTR CORRECTORS
US9546176B2 (en) 2012-11-20 2017-01-17 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic CFTR correctors
KR20150132483A (ko) * 2013-03-15 2015-11-25 디스커버리바이오메드 인코포레이티드 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
MA43775A (fr) 2016-04-07 2021-05-05 Proteostasis Therapeutics Inc Analogues du ivacaftor conentant des atomes de silicium
MA45397A (fr) 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
AU2017348186A1 (en) 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc Pyridazine derivatives, compositions and methods for modulating CFTR
CA3041675A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
MA49061A (fr) 2017-04-28 2021-04-21 Proteostasis Therapeutics Inc Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
AU2018346602B2 (en) 2017-10-06 2024-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing CFTR activity
WO2019136314A1 (en) 2018-01-05 2019-07-11 The Curators Of The University Of Missouri Compounds and methods for treatment of cystic fibrosis
AU2019334684B2 (en) 2018-09-09 2025-03-06 Qanatpharma Ag Use of CFTR modulators for treating cerebrovascular conditions
CN110156761B (zh) * 2019-06-18 2022-08-09 郑州大学 含香豆素-联苯骨架化合物、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566580A (en) * 1978-11-11 1980-05-20 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003245935A1 (en) 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
CN101076703A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
MX2007004488A (es) * 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
EP1799659A1 (en) * 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
CN101351208A (zh) * 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
US20090012148A1 (en) * 2005-11-01 2009-01-08 Maxfield Frederick R Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
WO2009076665A1 (en) * 2007-12-13 2009-06-18 Indiana University Research And Technology Corporation Materials and methods for inhibiting mammalian s-nitrosoglutathione reductase
WO2010111713A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
ITMI20111068A1 (it) * 2011-06-14 2012-12-15 Azienda Ospedaliera Universitaria I Ntegrata Di Ve Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
KR20150132483A (ko) 2013-03-15 2015-11-25 디스커버리바이오메드 인코포레이티드 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법

Also Published As

Publication number Publication date
EP2970248A4 (en) 2017-01-11
US9815825B2 (en) 2017-11-14
JP6514680B2 (ja) 2019-05-15
AU2014240026B2 (en) 2018-06-14
KR20150131309A (ko) 2015-11-24
WO2014152213A2 (en) 2014-09-25
AU2014240026A1 (en) 2015-08-20
CN105121437B (zh) 2018-12-04
CN105121437A (zh) 2015-12-02
JP2016515131A (ja) 2016-05-26
WO2014152213A3 (en) 2014-11-13
CA2903103C (en) 2020-06-09
HK1218420A1 (en) 2017-02-17
CA2903103A1 (en) 2014-09-25
US20160024065A1 (en) 2016-01-28
MX2015013173A (es) 2016-04-04
EP2970248A2 (en) 2016-01-20
EP2970248B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
MX372775B (es) Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.
WO2014081821A3 (en) Small Molecule Bicyclic and Tricyclic CFTR Correctors
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
MX2018000688A (es) Triciclicos sustituidos y metodo para usarlos.
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122292T1 (el) Ενωσεις και μεθοδοι για αντιϊικη αγωγη
CY1118823T1 (el) Παραγωγα πυριδινης και πυραζινης για την θεραπευτικη αντιμετωπιση της χρονιας αποφρακτικης πνευμονοπαθειας
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX389354B (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
JOP20240037A1 (ar) مركبات الإندول وطرق الاستخدام
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
HK1217092A1 (zh) 治疗性化合物及其用途
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA201692298A1 (ru) Производные карбоксамидов
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
PH12016501975A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide

Legal Events

Date Code Title Description
FG Grant or registration